Blake Chapman, DO
General Practice · Moose Lake, MNNPI 1205324209
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $156 and has fallen 80.6% since, to $30 in 2025.
Across 27 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$85
- AstraZeneca$70
- Boehringer Ingelheim$49
- AbbVie$46
- Astellas Pharma US Inc$36
- Pulmonx Corporation$27
- plus $134 from 9 others
Across 4 payments — averaging $12,495 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Diasorin Inc.$50K
What the payments were for
- Food & beverage$447100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 5 | $85 |
| AstraZeneca | 5 | $70 |
| Boehringer Ingelheim | 3 | $49 |
| AbbVie | 2 | $46 |
| Astellas Pharma US Inc | 2 | $36 |
| Pulmonx Corporation | 1 | $27 |
| Eisai Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Novo Nordisk | 1 | $14 |
| Pfizer | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Baxter Healthcare | 1 | $13 |
| Morphosys, US Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$447 in reported general payments places this provider in the 65th percentile of 1,478 general practice providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 26 | $37,095 |
| XareltoRivaroxaban | 24 | $24,511 |
| EliquisApixaban | 16 | $16,046 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $11,084 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $3,543 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,967 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $2,790 |
| Fentanyl | 12 | $2,553 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 46 | $1,304 |
| Metoprolol Succinate | 66 | $1,135 |
| Atorvastatin Calcium | 96 | $1,120 |
| Gabapentin | 50 | $886 |
| Celecoxib | 22 | $816 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $704 |
| Tamsulosin Hcl | 75 | $664 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $14 | $37,09526 claims |
| PfizerEliquis | $13 | $16,04616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,478 general practice providers in Minnesota.
Other general practice in Moose Lake
- Michael SkramstadOrono$186K
- Thomas MeschkeChaska$138K
- Frank MilnarSaint Paul$126K
- Lauren NuthWoodbury$90K
- Geoffrey SuditMinnetonka$89K
- Douglas LambertEdina$69K
- Mark MalterudSaint Paul$37K
- Paul SchultzMahtomedi$33K
- Bradley HolmbergEagle Lake$26K
- Marko KamelSavage$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.